Chepurnov A A, Ternovoĭ V A, Dadaeva A A, Dmitriev I P, Sizikova L P, Volchkov V E, Kudoiarova N M, Rudzevich T N, Netesov S V
Vopr Virusol. 1997 May-Jun;42(3):115-20.
Immunological and biochemical parameters were studied in guinea pigs immunized with recombinant vaccinia virus containing full-sized gene of Ebola virus vp24 protein and then infected with virulent strain of Ebola virus. The majority of the studied parameters changed similarly in guinea pigs immunized with recombinant vaccinia virus and control guinea pigs inoculated with vaccinia virus both before and after challenge with Ebola virus. However, in animals immunized with recombinant vaccinia virus producing vp24 some biochemical parameters, the mean life span after challenge with Ebola virus, the level of antibodies to the virus, and the phagocytic activity of neutrophils indicated the development of immunological processes other than in controls, namely, the development of immune response to vp24. Although these processes did not eventually lead to the survival of animals, they prolonged the mean life span and resulted in the production of anti-Ebola antibodies, though the level thereof was low. These data demonstrate that recombinant vaccines against Ebola fever are a promising trend of research.
对用含有埃博拉病毒vp24蛋白全长基因的重组痘苗病毒免疫、随后感染埃博拉病毒强毒株的豚鼠的免疫和生化参数进行了研究。在用重组痘苗病毒免疫的豚鼠和接种痘苗病毒的对照豚鼠中，大多数研究参数在感染埃博拉病毒前后的变化相似。然而，在用产生vp24的重组痘苗病毒免疫的动物中，一些生化参数、感染埃博拉病毒后的平均寿命、病毒抗体水平以及中性粒细胞的吞噬活性表明，其免疫过程的发展与对照不同，即对vp24产生了免疫反应。尽管这些过程最终并未导致动物存活，但它们延长了平均寿命并产生了抗埃博拉抗体，尽管抗体水平较低。这些数据表明，抗埃博拉热重组疫苗是一个有前景的研究方向。
